Molecular Imaging and Nuclear MedicineMolecular imaging and therapy of somatostatin receptor positive tumors

Add time:08/27/2019    Source:sciencedirect.com

Somatostatin receptors (SSTR) are upregulated in the cells of origin that define numerous neuroendocrine neoplasms. PET imaging with 68Ga-DOTATATE allows specific targeting of SSTR2A, a single species of SSTR receptor, which is commonly overexpressed in a variety of gastroenteropancreatic neuroendocrine tumors, as well as pulmonary carcinoid and head and neck tumors. Due to more specific targeting of SSTR2 as well as lower radiation dose, shorter study length, ability to quantify uptake, and lower cost, 68Ga-DOTATATE has demonstrated superior imaging attributes when compared to 111In-pentetreotide. As with any novel imaging modality, dedicated training, increasing experience and staying up-to-date with scientific publications are required to provide optimal patient care. The purpose of this review is to summarize the current state of the art in SSTR-targeted molecular imaging and discuss ongoing and future potential diagnostic and therapeutic applications.

We also recommend Trading Suppliers and Manufacturers of somatostatin 34 (cas 132894-19-0). Pls Click Website Link as below: cas 132894-19-0 suppliers

Prev:Migration of secondary tert-butyldimethylsilyl groups in cyclomalto-heptaose and -octaose derivatives
Next:Research articleLong-lasting actions of somatostatin on pyramidal cell excitability in the mouse cingulate cortex)